^(188)Re标记放射性药物研究进展

Development of ^(188)Re-Labeled Radiopharmaceuticals

188W/188Re发生器的发展极大提高了188Re在各种疾病治疗中的应用1。88Re是一种非常理想的治疗用放射性核素。已经开发了许多新的188Re标记的放射性药物并普遍地应用于临床试验中。188 Re-MAG31、88Re-DTPA用于防止冠状动脉再狭窄,188Re-HEDP1、88Re-ABP1、88Re-EDTMP等用于骨痛缓解的治疗,188Re-HDD碘化油溶液用于治疗肝癌,188Re标记的胶体和微球用于治疗关节炎及其他的实质性肿瘤。然而,仍需要发展新的靶向性更强的188Re标记的放射性药物如肿瘤特异的单克隆抗体和肽及葡萄糖类似物1。88Re从发生器可方便地获得以及合理的价格使188Re标记药物的临床应用前景广阔。

The development of a ^188W/^188 Re-generator has greatly promote the use of 188Re for treating various disease. ^188 Re is an ideal therapeutic radionuclide. Many new radiopharmaceuticals labeled by ^188 Re have been synthesized and are currently used in clinical trials, such as ^188 Re-MAG3 ^188 Re-DTPA for prevention of coronary arterial restenosis;^188 Re-HEDP ^188 Re-ABP ^188 Re-EDTMP for palliation of bone metastases pain; ^188 Re-HDD for treatment of liver cancer; ^188 Re-labeled colloids and microspheres for treatment of rheumatoid arthritis and other solid tumors. However,there is still a need to develop new ^188 Re-labeled radiopharmaceuticals that are more specific for target lesions such as cancer-specific monoclonal antibodies and peptides. The availability of ^188Re from a generator and reasonable cost may help increase the clinical application of ^188 Re-labeled radiopharmaceuticals.